Aspire BioPharma, Inc. (ASBP) — Cash Flow Quality Index
Latest as of June 2023:
-0.10x
Aspire BioPharma, Inc. (ASBP) has a Cash Flow Quality Index of -0.10x as of June 2023. Operating cash flow of $-189.95K is below net income of $1.81 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore ASBP debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
-0.10x
Operating CF / Net Income
Operating Cash Flow
$-189.95K
USD
Net Income
$1.81 Million
USD
Data as of
Jun 2023
Most recent filing
Aspire BioPharma, Inc. Cash Flow Quality Index (2022–2023)
Historical Cash Flow Quality Index for Aspire BioPharma, Inc. across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see ASBP cash flow metrics.
Annual Cash Flow Quality Index for Aspire BioPharma, Inc. (2022–2023)
Year-by-year earnings quality comparison for Aspire BioPharma, Inc..
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | -0.15x | $-653.11K | $4.46 Million | ▲ +65.3% |
| 2022 | -0.42x | $-1.41 Million | $3.34 Million | — |
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.